Corgenix Medical Corp, Denver, a worldwide developer and marketer of diagnostic test kits, is offering its AspirinWorks test to physicians and other labs through Quest Diagnostics Inc, Madison, NJ.
The test is an enzyme-linked immunoassay (ELISA) to determine levels of 11 dehydro thromboxane B2 (11dhTxB2) in human urine, which aids in the qualitative detection of aspirin effect in apparently healthy individuals post ingestion.
It determines the effect of aspirin on platelets by measuring the level of thromboxane production (aspirin’s target). The higher the levels of thromboxane, the stickier the blood platelets, and the less impact the aspirin is having. The information allows physicians to individualize a patient’s therapy.
The test was launched in 2007 following FDA 510(k) clearance, and is available nationwide through national and regional clinical labs.
It will be featured at several upcoming scientific meetings, including the American College of Osteopathic Family Physicians in March, the American College of Cardiology in March, and the American College of Physicians in May.
